AUL
RXRX icon

AlphaGrep UK Ltd’s Recursion Pharmaceuticals RXRX Stock Holding History

AlphaGrep UK Ltd’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,063
Closed -$135K – 914
2025
Q4 		$135K Buy
+33,063
New +$164K 0.05% 645

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AlphaGrep UK Ltd's RXRX Position: Q1 2026 in Review

AlphaGrep UK Ltd sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 33,063 shares — an estimated $135K sold.

AlphaGrep UK Ltd first reported a position in RXRX in Q4 2025 and held it in 1 quarter. The position peaked at $135K in Q4 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • AlphaGrep UK Ltd reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AlphaGrep UK Ltd sold 33,063 Recursion Pharmaceuticals shares in Q1 2026, an estimated $135K.
  • AlphaGrep UK Ltd first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • AlphaGrep UK Ltd's Recursion Pharmaceuticals position peaked at $135K in Q4 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.